Inventor · disambiguated record
Scott R. Daigle
Also filed as: DAIGLE SCOTT · DAIGLE SCOTT R · DAIGLE SCOTT RICHARD
9 granted patents·17 pending applications·114 citations·filing 2011–2023
89Inventor score
Top patents by PatentIndex Score
26 records- 0195US9446064B2Combination therapy for treating cancerEPIZYME INC·Filed 2014·Granted Sep 20, 2016·22 cites·23 claims
- 0294US8580762B2Substituted purine and 7-deazapurine compoundsOLHAVA EDWARD JAMES·Filed 2011·Granted Nov 12, 2013·37 cites·6 claims
- 0393US10525074B2Combination therapy for treating cancerEPIZYME INC·Filed 2016·Granted Jan 7, 2020·7 cites·23 claims
- 0493US9096634B2Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2013·Granted Aug 4, 2015·17 cites·20 claims
- 0592US10881680B2Method of treating leukemiaEPIZYME INC·Filed 2018·Granted Jan 5, 2021·3 cites·20 claims
- 0692US9597348B2Method of treating leukemiaEPIZYME INC·Filed 2013·Granted Mar 21, 2017·15 cites·18 claims
- 0789US10143704B2Methods for treating cancerEPIZYME INC·Filed 2014·Granted Dec 4, 2018·8 cites·19 claims
- 0883US11602529B2Use of EZH2 inhibitors for treating cancerEPIZYME INC·Filed 2018·Granted Mar 14, 2023·5 cites·17 claims
- 0974US11633420B2Method of treating leukemiaEPIZYME INC·Filed 2021·Granted Apr 25, 2023·0 cites·13 claims
- 1071US2021252035A1Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2020·Application pending·0 cites
- 1164US2022193084A1Inhibitors of ezh2 and methods of use thereofEPIZYME INC·Filed 2021·Application pending·0 cites
- 1264US2020113923A1Dot1l inhibitors for use in the treatment of leukemiaEPIZYME INC·Filed 2019·Application pending·0 cites
- 1362US2023181549A1Use of ezh2 inhibitors for treating cancerEPIZYME INC·Filed 2023·Application pending·0 cites
- 1461US2018280422A1Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2017·Application pending·0 cites
- 1561US2020009176A1Treatment of leukemia via the administration of dot1l inhibitor pinometostatEPIZYME INC·Filed 2019·Application pending·0 cites
- 1660US2020030355A1Combination therapy for treating cancerEPIZYME INC·Filed 2019·Application pending·0 cites
- 1756US2017165288A1Method of treating leukemiaEPIZYME INC·Filed 2016·Application pending·0 cites
- 1855US2015366893A1Substituted purine and 7-deazapurine compoundsEPIZYME INC·Filed 2015·Application pending·0 cites
- 1952US2021052595A1Inhibitors of ezh2 and methods of use thereofEPIZYME INC·Filed 2016·Application pending·0 cites
- 2052US2016045531A1Combination therapy for treating cancerEPIZYME INC·Filed 2014·Application pending·0 cites
- 2151US2019076455A1Treatment of leukemia via the administration of dot1l inhibitor pinometostatEPIZYME INC·Filed 2015·Application pending·0 cites
- 2251US2017232030A1Combination therapy for treating cancerEPIZYME INC·Filed 2015·Application pending·0 cites
- 2351US2015342979A1Dot1l inhibitors for use in the treatment of leukemiaEPIZYME INC·Filed 2013·Application pending·0 cites
- 2445US2023201212A1Inhibitors of ezh2 and methods of use thereofEPIZYME INC·Filed 2018·Application pending·0 cites
- 2541US2018028552A1Combination therapy for treating cancerEPIZYME INC·Filed 2016·Application pending·0 cites
- 2640US2019083521A1Combination therapy for treating cancerEPIZYME INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →